| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10484598 | Value in Health | 2016 | 8 Pages |
Abstract
Incobotulinumtoxin-A administered at flexible treatment intervals determined by the needs of the patient was found to be a cost-effective treatment option when compared to the administration of onabotulinumtoxin-A in the Australian health care system. The option to administer incobotulinumtoxin-A according to the needs of the patient resulted in patients experiencing symptoms for a fewer number of weeks compared to onabotulinumtoxin-A given at minimum 12-week intervals.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Dominic BCom, MPH, Carmel BSc, BSocSc, MPH,